Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Acute Lymphoblastic Leukemia/Lymphoma (ALL) is a type of cancer that affects the blood and bone marrow, where blood cells are made. It involves the rapid growth of immature white blood cells called lymphoblasts, which crowd out normal cells and impair the body's ability to fight infections, carry oxygen, and control bleeding. This condition mainly affects the immune system and blood production, leading to symptoms like fatigue, frequent infections, easy bruising, and bleeding. ALL can progress quickly without treatment and is most common in children but can occur at any age. The disease requires prompt diagnosis and specialized treatment to improve outcomes.

Acute Lymphoblastic Leukemia/Lymphoma (ALL) is a malignant proliferation of lymphoid progenitor cells in the bone marrow and sometimes lymphoid tissues, characterized by accumulation of lymphoblasts that fail to mature. It results from genetic alterations such as chromosomal translocations (e.g., t(12;21), t(9;22)) affecting genes like TEL-AML1 and BCR-ABL, leading to uncontrolled cell growth and impaired differentiation. The disease causes bone marrow failure with resultant anemia, thrombocytopenia, and neutropenia, and may infiltrate extramedullary sites including lymph nodes, liver, spleen, and central nervous system. ALL is the most common pediatric leukemia and has significant clinical importance due to its aggressive course and potential for cure with intensive chemotherapy. Immunophenotyping distinguishes B-cell from T-cell lineage, guiding prognosis and treatment.